Raymond James Trust N.A. Has $349,000 Holdings in Illumina, Inc. (NASDAQ:ILMN)

Raymond James Trust N.A. lessened its holdings in Illumina, Inc. (NASDAQ:ILMNGet Rating) by 9.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,831 shares of the life sciences company’s stock after selling 191 shares during the quarter. Raymond James Trust N.A.’s holdings in Illumina were worth $349,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ILMN. Brown Brothers Harriman & Co. raised its stake in shares of Illumina by 460.9% during the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock worth $45,000 after purchasing an additional 106 shares in the last quarter. Private Trust Co. NA acquired a new stake in Illumina in the second quarter valued at $25,000. Glassman Wealth Services lifted its stake in Illumina by 72.9% in the second quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock valued at $27,000 after acquiring an additional 62 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its position in shares of Illumina by 50.0% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock valued at $35,000 after acquiring an additional 61 shares during the period. Finally, Penserra Capital Management LLC acquired a new position in shares of Illumina during the 1st quarter worth about $64,000. Institutional investors and hedge funds own 87.97% of the company’s stock.

Insider Activity

In other Illumina news, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $223.65, for a total value of $111,825.00. Following the transaction, the senior vice president now owns 40,112 shares in the company, valued at $8,971,048.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $223.65, for a total transaction of $111,825.00. Following the sale, the senior vice president now directly owns 40,112 shares of the company’s stock, valued at approximately $8,971,048.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Aimee L. Hoyt sold 871 shares of the stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $205.57, for a total transaction of $179,051.47. Following the completion of the transaction, the senior vice president now directly owns 2,796 shares of the company’s stock, valued at approximately $574,773.72. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,371 shares of company stock worth $499,481. Insiders own 0.13% of the company’s stock.

Illumina Trading Up 3.8 %

Shares of Illumina stock opened at $201.11 on Monday. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.07. Illumina, Inc. has a 12-month low of $173.45 and a 12-month high of $405.62. The company has a market capitalization of $31.63 billion, a price-to-earnings ratio of -7.62 and a beta of 1.14. The firm’s 50-day moving average price is $210.18 and its two-hundred day moving average price is $207.27.

Illumina (NASDAQ:ILMNGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The life sciences company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.05. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a negative net margin of 88.40% and a positive return on equity of 4.36%. On average, analysts forecast that Illumina, Inc. will post 2.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research analyst reports. Citigroup cut Illumina from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $200.00 to $180.00 in a report on Monday, December 12th. Argus dropped their price target on Illumina from $300.00 to $250.00 in a research note on Tuesday, October 11th. Credit Suisse Group cut their price target on Illumina from $230.00 to $225.00 and set a “neutral” rating for the company in a report on Friday, November 4th. Barclays upped their price objective on shares of Illumina from $130.00 to $175.00 and gave the company an “underweight” rating in a report on Friday, September 30th. Finally, StockNews.com began coverage on shares of Illumina in a report on Wednesday, October 12th. They set a “hold” rating for the company. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $250.22.

Illumina Company Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Recommended Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNGet Rating).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.